Portugal now part of MRA with FDA
Recommendation

2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
After a positive assessment, the US Food and Drug Administration (FDA) has approved Portugal to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
The total number of countries accepted by the FDA is now 15: Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Other EU member states will be added as their evaluation is completed by the US. According to a previous EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Source: EMA Press Release entitled "Portugal to also benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
01.07.2026Should TGA publish GMP Certificates?
24.06.2026Quality Unit (QU) in the Focus of a Warning Letter: Oversight Failures and FDA Expectations
03.06.2026GMP Auditor Association Developments January through April 2026
20.05.2026CAPA and Root Cause Analysis - why FDA keeps calling them out
20.05.2026FDA Pilots One-Day Inspectional Assessments to Expand Oversight


